Cara Therapeutics Inc. diskutieren
Cara Therapeutics Inc.
WKN: A1XDTK / Symbol: CARA / Name: Cara / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,67 €
-2,47 %
Sell Cara Therapeutics Inc.
Cara Therapeutics, Inc. (NASDAQ: CARA) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at HC Wainwright from $15.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at Needham & Company LLC from $22.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.50. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat
Neueste Beiträge
StockNews_com in Universal Technical Institute diskutieren